ABSTRACT
Background: The pathogenesis of autism spectrum disorder (ASD) is under investigation and one of the main alterations relates to the metabolic and inflammatory system dysfunctions. Indeed, based on a possible deficit of omega-3 fatty acids (FAs) of patients with ASD and looking for an anti-inflammatory effect, dietary supplements with omega-3 fatty acids have been proposed. We aimed to evaluate differences in plasma and erythrocyte FA profiles and plasma cytokines in patients with infantile ASD after supplementation with docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids or placebo and both compared at baseline with a reference healthy group. Methods: A double-blind, randomized placebo-controlled intervention with DHA/EPA for 6 months was carried out in 54 children between 2 and 6 years diagnosed with ASD. They were selected and randomly assigned into two groups: 19 children received 800 mg/day of DHA and 25 mg/day of EPA, or placebo. In addition, another reference group of 59 healthy children of the same age was included. Plasma lipids and cytokines, and FA profiles in plasma and erythrocytes were measured at baseline and after 6 months of treatment in ASD children, and at baseline in the reference group. Results: There were no differences in demographic, anthropometric characteristics, and omega-3 intake between the healthy reference group and the ASD children at baseline. Children with ASD showed the higher plasma percentages of palmitic acid and total saturated FA and lower total omega-6 polyunsaturated FA (PUFA) compared with healthy children. An increased level of DHA and reduced EPA level in erythrocytes were detected in the ASD group vs. the reference group. After 6 months of treatment, the ASD group that received DHA enriched product significantly increased the plasma and erythrocyte percentages of DHA, but no differences were observed in the clinical test scores and other parameters as plasma cytokines between the two groups of ASD related to the intervention. Conclusion: Spanish children with ASD exhibit an appropriate omega-3 FA status in plasma and erythrocytes. Neither a clinical improvement of ASD children nor a better anti-inflammatory or fatty acid state has been found after an intervention with DHA/EPA for 6 months. So, the prescription of n-3 LC-PUFA and other dietary supplements in ASD should be only indicated after a confirmed alteration of FA metabolism or omega-3 LC-PUFA deficiency evaluated by specific erythrocyte FA. Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT03620097].
ABSTRACT
Hydroxytyrosol (HT) from olives and polyphenols from almond skin (ASPs) possess cardioprotective properties. This pilot study evaluates the effect of supplementation with a combination of olive fruit and almond skin extracts on low-density lipoprotein (LDL) cholesterol oxidation, lipid homeostasis, and inflammatory parameters in adults with moderate hypercholesterolemia. A randomized, parallel, double-blind, placebo-controlled pilot study of 8 weeks was performed. The extract group (EG) received the supplement with 7.5 mg HT +210 mg ASPs, and the control group (CG) received a placebo composed of maltodextrin. Oxidized LDL (oxLDL) levels and the oxLDL/LDL ratio were lower in the EG than in the CG after 8 weeks of treatment (18.76 ± 3.91 vs. 10.34 ± 4.22, P < .001 and 0.151 ± 0.025 vs. 0.08 ± 0.023, P < .001, respectively). Interleukin-1ß levels were significantly higher in the CG than in the EG at week 4 (P = .004), IL-6 was significantly higher in the CG than in the EG at week 4 (P = .049), and IL-10 was significantly increased at week 4 in both groups (P = .002 for CG and P = .001 for EG). In conclusion, daily consumption of a combination of an olive fruit extract and an almond skin extract for 8 weeks seems to protect LDL from oxidation and to prevent inflammatory status in moderately hypercholesterolemic subjects.
Subject(s)
Olea , Prunus dulcis , Adult , Double-Blind Method , Fruit , Humans , Inflammation , Lipoproteins, LDL , Oxidative Stress , Pilot Projects , Plant ExtractsABSTRACT
The aim of this study was to evaluate the effect of two doses of d-chiro-inositol (DCI) in combination with Myo-inositol (MYO) on the oocyte quality (OQ) of women with polycystic ovarian syndrome (PCOS) undergoing intracytoplasmic sperm injection (ICSI). Methods: This was a controlled, randomized, double-blind, parallel group study on 172 oocytes from 11 women. The study compared the effect of two MYO-DCI formulations given over 12 weeks on OQ. Five women received 550 mg of MYO + 300 mg of DCI daily (high DCI content group), while 6 women were given a daily dose of 550 mg of MYO with the only 27.6 mg of DCI (low DCI content group). Results: According to a multivariate analysis using linear mixed effect models, high doses of DCI have a positive influence on the quality of the cytoplasm of the oocyte (ß = 1.631, χ2 = 7.347, d.f. = 1, p = .00672). Zona pellucida, plasma membrane, cytoplasm, and sperm reception have also been improved with any combination of MYO/DCI by decreasing testosterone or improving insulin sensitivity, regardless of age and body mass index. Conclusion: The combination of MYO with high doses of DCI improved oocyte cytoplasm quality in women with PCOS undergoing ICSI.
Subject(s)
Infertility, Female/drug therapy , Inositol/administration & dosage , Oocytes/drug effects , Polycystic Ovary Syndrome/complications , Vitamin B Complex/administration & dosage , Adult , Double-Blind Method , Female , Humans , Infertility, Female/etiology , Sperm Injections, IntracytoplasmicABSTRACT
BACKGROUND: Obesity is characterized by increased fat mass and is associated with the development of insulin resistance syndrome (IRS), usually known as metabolic syndrome. The alteration of the intestinal microbiota composition has a role in the development of IRS associated with obesity, and probiotics, which are live microorganisms that confer a health benefit to the host, contribute to restore intestinal microbiota homeostasis and lower peripheral tissue insulin resistance. We aim to evaluate the effects of the probiotic strain Lactobacillus reuteri (L. reuteri) V3401 on the composition of intestinal microbiota, markers of insulin resistance and biomarkers of inflammation, cardiovascular risk, and hepatic steatosis in patients with overweight and obesity exhibiting IRS. METHODS/DESIGN: We describe a randomized, double-blind, crossover, placebo-controlled, and single-centre trial. Sixty participants (aged 18 to 65 years) diagnosed with IRS will be randomized in a 1:1 ratio to receive either a daily dose of placebo or 5 × 109 colony-forming units of L. reuteri V3401. The study will consist of two intervention periods of 12 weeks separated by a washout period of 6 weeks and preceded by another washout period of 2 weeks. The primary outcome will be the change in plasma lipopolysaccharide (LPS) levels at 12 weeks. Secondary outcomes will include anthropometric parameters, lipid profile, glucose metabolism, microbiota composition, hepatic steatosis, and inflammatory and cardiovascular biomarkers. Blood and stool samples will be collected at baseline, at the midpoint (only stool samples) and immediately after each intervention period. Luminex technology will be used to measure interleukins. For statistical analysis, a mixed ANOVA model will be employed to calculate changes in the outcome variables. DISCUSSION: This is the first time that L. reuteri V3401 will be evaluated in patients with IRS. Therefore, this study will provide valuable scientific information about the effects of this strain in metabolic syndrome patients. TRIAL REGISTRATION: The trial has been retrospectively registered in ClinicalTrials.gov on the 23rd November 2016 (ID: NCT02972567 ), during the recruitment phase.
Subject(s)
Limosilactobacillus reuteri/physiology , Metabolic Syndrome/drug therapy , Obesity/drug therapy , Probiotics/administration & dosage , Adolescent , Adult , Aged , Biomarkers/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Cardiovascular Diseases/genetics , Cardiovascular Diseases/immunology , Double-Blind Method , Fatty Liver/blood , Fatty Liver/etiology , Fatty Liver/genetics , Fatty Liver/immunology , Female , Gastrointestinal Microbiome , Humans , Insulin Resistance , Male , Metabolic Syndrome/complications , Metabolic Syndrome/immunology , Metabolic Syndrome/microbiology , Middle Aged , Obesity/complications , Obesity/immunology , Obesity/microbiology , Risk Factors , Young AdultABSTRACT
We have undertaken a magnetic study on the oral biodistribution and biodegradation of nude maghemite nanoparticles of 10 nm average size (MNP) and probiotic bacteria, Lactobacillus fermentum, containing thousands of these same nanoparticles (MNP-bacteria). Using AC magnetic susceptibility measurements of the stomach, small intestine, cecum and large intestine obtained after rat sacrifice, and iron content determination by ICP-OES, we have monitored the biodistribution and biodegradation of the maghemite nanoparticles along the gastrointestinal tract, after oral administration of both MNP and MNP-bacteria. The results revealed that the amount of magnetic nanoparticles accumulated in intestines is sensibly higher when MNP-bacteria were administered, in comparison with MNP. This confirms our initial hypothesis that the use of probiotic bacteria is a suitable strategy to assist the magnetic nanoparticles to overcome the stomach medium, and to achieve their accumulation in intestines. This finding opens doors to different applications. Since iron absorption in humans takes place precisely in the intestines, the use of MNP-bacteria as an iron supplement is a definite possibility. We have actually illustrated how the administration of MNP-bacteria to iron-deficient rats corrects the iron levels after two weeks of treatment.
Subject(s)
Gastrointestinal Tract/metabolism , Iron/analysis , Magnetite Nanoparticles/analysis , Animals , Bacteria , Magnetics , Male , Probiotics , Rats , Rats, Wistar , Tissue DistributionABSTRACT
Probiotics have been used as alternative therapies in intestinal inflammatory disorders. Many studies have shown that different bacterial probiotic strains possess immuno-modulatory and anti-inflammatory properties. However, there is an increasing interest in the use of non-viable bacteria to reduce the risk of microbial translocation and infection. The aim of this study was to evaluate whether the viability of L. fermentum CECT5716 is essential to exert its intestinal anti-inflammatory effect. We compared the preventative effects of viable and non-viable probiotic in the TNBS model of rat colitis. In vitro studies were also performed in Caco-2 and RAW 264.7 cells to evaluate the probiotic effects on IL-8, IL-1ß and nitrite production, and p44/42 and p38 MAP kinase protein expressions. In vitro results revealed a decrease in the stimulated production of pro-inflammatory mediators regardless of the viability of the probiotic. Likewise, both forms of the probiotic administered to colitic rats produced a significant reduction of IL-1ß and TNF-α levels and colonic iNOS expression. In conclusion, both live and dead L. fermentum CECT5716 have been demonstrated to attenuate the inflammatory process and diminish the production of some of the inflammatory mediators. In fact, the viability of this probiotic did not affect its immuno-modulatory and anti-inflammatory properties.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Limosilactobacillus fermentum , Microbial Viability , Probiotics , Animals , Caco-2 Cells , Colitis/microbiology , Colitis/therapy , Female , Gastrointestinal Microbiome , Humans , Immunomodulation , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/metabolism , Interleukin-8/antagonists & inhibitors , Interleukin-8/metabolism , Intestinal Mucosa/metabolism , Intestines/microbiology , Mice , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/metabolism , Nitric Oxide/antagonists & inhibitors , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , RAW 264.7 Cells , Rats , Rats, Wistar , Trinitrobenzenesulfonic Acid/adverse effects , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
OBJECTIVES: The aim of the study was to examine the effects of a follow-on formula containing Lactobacillus fermentum CECT5716 (L. fermentum) on the incidence of infections in infants between the ages of 6 and 12 months. PATIENTS AND METHODS: A randomized double-blinded controlled study including infants at the age of 6 months was conducted. Infants were assigned randomly to either follow-on formula supplemented with L. fermentum plus galactooligosaccharide (experimental group, EG), or the same formula supplemented with only galactooligosaccharide (control group, CG). The main outcome was the incidence of infections for the 6-month duration of the study. RESULTS: The EG showed a significant 46% reduction in the incidence rate (IR) of gastrointestinal infections (EG: 0.196â±â0.51, CG: 0.363â±â0.53, IR ratio 0.54, 95% confidence interval [CI] 0.307-0.950, Pâ=â0.032), 27% reduction in the incidence of upper respiratory tract infections (EG: 0.969â±â0.96, CG: 1.330â±â1.23, IR ratio 0.729, 95% CI 0.46-1.38, Pâ=â0.026), and 30% reduction in the total number of infections (EG: 1.464â±â1.15, CG: 2.077â±â1.59, IR ratio 0.70, 95% CI 0.46-1.38, Pâ=â0.003), at the end of the study period compared with CG. CONCLUSIONS: Administration of a follow-on formula with L. fermentum CECT5716 may be useful for the prevention of community-acquired gastrointestinal and upper respiratory infections.
Subject(s)
Food Microbiology , Gastrointestinal Diseases/prevention & control , Infant Formula , Limosilactobacillus fermentum , Milk, Human/microbiology , Probiotics/therapeutic use , Respiratory Tract Infections/prevention & control , Dietary Supplements , Double-Blind Method , Female , Gastrointestinal Diseases/epidemiology , Humans , Incidence , Infant , Infant Formula/chemistry , Male , Respiratory Tract Infections/epidemiologyABSTRACT
OBJECTIVE: Intestinal microbiota plays an important role in the prevention of certain diseases during the pediatric years. Thus, there is an increasing interest in the addition of probiotics to infant formulas. The aim of this study was to evaluate the safety of a follow-on formula with Lactobacillus salivarius CECT5713 in 6-mo-old children. METHODS: The antibiotic susceptibility of L. salivarius CECT5713 was analyzed by a dilution method. A double-blinded, randomized, placebo controlled study was performed. Children (n = 80) were distributed in two groups and consumed the formula supplemented or not with probiotics (2 × 10(6) colony-forming units [cfu]/g) during 6 mo. Fecal samples were collected at enrollment, at 3 mo, and at the end of trial. Clinical and anthropometric evaluations were performed. Depending on the variable, one-way or two-way repeated measures analysis of variance were used for the statistical analysis. RESULTS: The antibiotic susceptibility profile of the strain resulted as safe. No adverse effects associated with the consumption of the probiotic formula were reported. In addition, clinical parameters did not differ between groups. Consumption of the probiotic supplemented formula led to an increase in the fecal lactobacilli content (7.6 ± 0.2 versus 7.9 ± 0.1 log cfu/g, P < 0.05). Lactobacillus salivarius CECT5713 was detected in the feces of volunteers from the probiotic group. Probiotic consumption induced a significant increase in the fecal concentration of butyric acid at 6 mo. CONCLUSION: Thus, a follow-on formula with L. salivarius CECT5713 is safe and well tolerated in 6-mo-old infants.
Subject(s)
Food Microbiology , Infant Formula , Lactobacillus , Milk, Human/microbiology , Probiotics/administration & dosage , Anti-Bacterial Agents/pharmacology , Butyric Acid/analysis , Diarrhea, Infantile/epidemiology , Diarrhea, Infantile/prevention & control , Double-Blind Method , Feces/chemistry , Feces/microbiology , Female , Gastrointestinal Tract/physiology , Humans , Infant , Lactobacillus/drug effects , Lactobacillus/growth & development , Lactobacillus/isolation & purification , Male , Microbial Sensitivity Tests , Microbial Viability , Probiotics/adverse effects , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/prevention & control , Time Factors , Water/analysisABSTRACT
Breast milk is the best food for the neonate because it provides a unique combination of proteins, carbohydrates, lipids, minerals and vitamins that ensures the correct growth and development of the infant. In addition, it also contains bioactive compounds responsible for a wide range of beneficial effects such as the promotion of immune system maturation and the protection against infections. Among these bioactive agents, probiotic bacteria have been recently isolated from human milk. The present work reviews the beneficial effects of these bacteria both in animal models and in clinical trials. The promotion of immune system maturation and defence against infections as well as the anti-inflammatory properties are among the main healthy effects of these bacteria. The isolation of probiotic bacteria with beneficial effects for the host provides scientific support for the supplementation of infant formula with these bacteria, in order to advance the pursuit of the main goal of formula: to mimic breast milk and its functional effects as closely as possible.
Subject(s)
Lactobacillus/isolation & purification , Milk, Human/microbiology , Probiotics , Bacterial Infections/prevention & control , Breast Feeding , Female , Humans , Immune System/growth & development , Infant, Newborn , Intestines/immunology , Intestines/microbiology , Lactobacillus/classification , Virus Diseases/prevention & controlABSTRACT
OBJECTIVE: We studied the coadjuvant capability of oral consumption of the breast-milk-isolated strain Lactobacillus fermentum (CECT5716) for an anti-influenza vaccine. METHODS: A randomized, double-blinded, placebo-controlled human clinical trial including 50 volunteers (31 male and 19 female) was performed to address the immunologic effects of an intramuscular anti-influenza vaccine in adults (33.0 +/- 7.7 y old). Fifty percent of volunteers received an oral daily dose of methylcellulose (placebo) or probiotic bacteria (1 x 10(10) colony-forming units/d) 2 wk before vaccination and 2 wk after vaccination. RESULTS: Two weeks after vaccination there was an increase in the proportion of natural killer cells in the probiotic group but not in the placebo group. The vaccination induced an increase in T-helper type 1 cytokine concentrations and in T-helper and T-cytotoxic proportions in both groups; however, the probiotic group showed a significant higher induction in some of these parameters. Regarding the humoral effects, induction of antibody response in the placebo group could not be detected. In the case of the probiotic group, a significant increase in antigen specific immunoglobulin A was detected. Although an increase in total immunoglobulin M was observed, changes in anti-influenza antigen specific immunoglobulin M were not observed. The incidence of an influenza-like illness during 5 mo after vaccination (October to February) was lower in the group consuming the probiotic bacteria. CONCLUSION: Oral administration of the strain L. fermentum CECT5716 potentates the immunologic response of an anti-influenza vaccine and may provide enhanced systemic protection from infection by increasing the T-helper type 1 response and virus-neutralizing antibodies.
Subject(s)
Antibody Formation , Immunity, Cellular , Influenza Vaccines/immunology , Limosilactobacillus fermentum/immunology , Probiotics , Adjuvants, Immunologic/administration & dosage , Administration, Oral , Adult , Antibodies, Viral/biosynthesis , Dietary Supplements , Double-Blind Method , Female , Humans , Male , Probiotics/administration & dosage , Time FactorsABSTRACT
The higher incidence of inflammatory diseases in Western countries might be related, in part, to a high consumption of saturated fatty acids and n-6 polyunsaturated fatty acids (PUFA) and an insufficient intake of n-3 fatty acids. The purpose of this study was to examine the effects of dietary n-3 fatty acids on innate and specific immune response and their anti-inflammatory action in models of contact and atopic dermatitis. Balb/C mice were fed for 3 wk either n-6 or n-3 PUFA-fortified diets. After inducing a contact or an atopic dermatitis, immunological parameters were analyzed to evaluate the anti-inflammatory potential of these n-3 PUFA. n-3 PUFA reduced innate and specific immune responses through inhibition of TH1 and TH2 responses, increase of immunomodulatory cytokines such as IL-10, and regulation of gene expression. The inhibition of both kinds of responses was confirmed by the anti-inflammatory effect observed in contact and atopic dermatitis. Reduction in weight, edema, thickness, leukocyte infiltration, and enhancement of antioxidant defenses in the inflamed ears of mice from both models along with the prevention of delayed-type hypersensitivity induced in atopic dermatitis proved n-3 PUFA efficacy. Our data suggest that dietary fish oil-derived n-3 fatty acids have immunomodulatory effects and could be useful in inflammatory disorders.
Subject(s)
Cytokines/metabolism , Fatty Acids, Omega-3/pharmacology , Fish Oils/pharmacology , Inflammation/prevention & control , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/genetics , Dermatitis/prevention & control , Eicosanoids/metabolism , Enzyme-Linked Immunosorbent Assay , Fatty Acids, Omega-3/administration & dosage , Fish Oils/administration & dosage , Gene Expression/drug effects , Lipids/blood , Lymphocytes/cytology , Lymphocytes/drug effects , Lymphocytes/metabolism , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , PPAR alpha/genetics , PPAR gamma/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
BACKGROUND: Polyunsaturated fatty acids play a key role in a number of biological functions. Rice bran oil (RBO) is rich in linoleic acid, an essential n-6 fatty acid. n-6 fatty acids are said to have proinflammatory effects as a result of an increase in n-6 fatty acid-derived eicosanoids. RBO is also rich in gamma-oryzanol, a compound from the unsaponifiable fraction, with antioxidant properties. OBJECTIVE: The aim of this work is to examine the effect of RBO-and/or gamma-oryzanol-enriched diets on the regulation of the immune response. METHODS: 4 week-old Balb/C mice were fed diets enriched with either RBO or high oleic-sunflower oil (HOSO), for one month. Serum samples, bone marrow-derived macrophages and lymphocytes from the spleen were collected. RESULTS: Compared to HOSO, our results show that RBO modulates the immune system by enhancing B-lymphocyte proliferation (6842 +/- 2959 vs 10073 +/- 4186 cpm; HOSO vs RBO; n = 10 per group) and TH1-type cytokines such as IL-2 (55.85 +/- 18.2 vs 101.7 +/- 21.6 pg/ml) or TNF-alpha (49.12 +/- 18.6 vs 184.9 +/- 46.2 pg/ml; HOSO vs RBO) in a significant way (n = 10 per group). Moreover, the reduction found in the TH2 cytokine IL-4 (7.59 +/- 2.3 vs 4.48 +/- 1.6 pg/ml) and IgE (56.9 +/- 39.2 vs 42.4 +/- 35.2 ng/ ml; HOSO vs RBO, n = 10 per group) levels suggests RBO may have antiallergenic properties. To elucidate the role of gamma-oryzanol, a similar study was also carried out including diets enriched with refined RBO or HOSO containing gamma-oryzanol (2 %). Our results suggest that although gamma-oryzanol may modulate the immune system, it is not responsible for the overall immunostimulation effect seen for RBO. CONCLUSIONS: RBO-enriched diets could be useful in situations where a potentiation of the immune response was required. The fatty acids composition, more than the unsaponifiable fraction, might be responsible for this effect.